Press Detail

/
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG

Dreieich, 7 April 2017. Biotest AG, Tiancheng International Investment Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), affiliated companies controlled by Creat Group Corporation, have signed a Business Combination Agreement today. Tiancheng (Germany) Pharmaceutical Holdings AG announced today its decision to make a voluntary public takeover offer for all outstanding ordinary and preference shares of Biotest AG for EUR 28.50 per ordinary share and EUR 19.00 per preference share in an all-cash transaction. Subject to the terms and conditions of the Business Combination Agreement and their statutory fiduciary duties, in particular the review of the offer document to be published by Tiancheng (Germany) Pharmaceutical Holdings AG, Biotest AG's Management Board and Supervisory Board welcome and support the voluntary takeover offer. The offer will be subject to a minimum acceptance threshold of 75 percent of all ordinary shares as well as regulatory approvals.

Biotest AG has been informed that Biotest AG's majority shareholder, OGEL GmbH, supports the transaction and has agreed with Tiancheng International Investment Limited, Hong Kong, to irrevocably accept the offer and to tender its shares, which represent 50.61 percent of all outstanding ordinary shares.

The Management Board and the Supervisory Board of Biotest AG will provide a statement concerning this offer pursuant to their statutory duties upon publication of the offer document.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart